MONTREAL, QUEBEC -- (MARKET WIRE) -- January 30, 2007 -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that it has completed the preclinical PBI-1393 toxicology studies for an offshore clinical trial in patients with advanced cervical cancer.
